Effects and mechanism of Bielong ruangan decoction on liver cancer model rats

YIN Sihan; PENG Jing; LUO Lingwei; ZHOU Yi; HU Li

doi:10.6039/j.issn.1001-0408.2024.18.06

您当前的位置：

首页 >

文章列表页 >

Effects and mechanism of Bielong ruangan decoction on liver cancer model rats

更新时间：2024-09-25

- Effects and mechanism of Bielong ruangan decoction on liver cancer model rats
- ZHONGGUO YAOFANG Vol. 35, Issue 18, Pages: 2219-2224(2024)
- 作者机构：
  
  湖南中医药大学第一附属医院肝病研究所，长沙　410007
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2024.18.06
  CLC： R965
- Published：30 September 2024，
  
  Received：28 March 2024，
  
  Revised：23 August 2024，
- 稿件说明：
移动端阅览
银思涵,彭憬,罗凌威等.鳖龙软肝汤对肝癌模型大鼠的影响及作用机制 ^Δ[J].中国药房,2024,35(18):2219-2224.

YIN Sihan,PENG Jing,LUO Lingwei,et al.Effects and mechanism of Bielong ruangan decoction on liver cancer model rats[J].ZHONGGUO YAOFANG,2024,35(18):2219-2224.
银思涵,彭憬,罗凌威等.鳖龙软肝汤对肝癌模型大鼠的影响及作用机制 ^Δ[J].中国药房,2024,35(18):2219-2224. DOI： 10.6039/j.issn.1001-0408.2024.18.06.

YIN Sihan,PENG Jing,LUO Lingwei,et al.Effects and mechanism of Bielong ruangan decoction on liver cancer model rats[J].ZHONGGUO YAOFANG,2024,35(18):2219-2224. DOI： 10.6039/j.issn.1001-0408.2024.18.06.

摘要

目的

探讨鳖龙软肝汤对肝癌模型大鼠的影响及作用机制。

方法

将32只雄性SD大鼠随机分为对照组、模型组和鳖龙软肝汤低、高剂量组[6.84、27.36 g/（kg·d），以生药量计]，每组8只。除对照组外，其余各组大鼠均腹腔注射二乙基亚硝胺（DEN）50 mg/kg（每周1次，连续16周）以复制肝癌模型。于DEN注射第8周时，鳖龙软肝汤低、高剂量组大鼠灌胃相应药液，每天2次，给药至第16周。观察各组大鼠实验期间的一般状况。末次给药后，称定其体重和肝脏质量，计算肝指数；检测其血清丙氨酸转氨酶（ALT）、天冬氨酸转氨酶（AST）含量；观察其肝脏外观、病理形态和纤维化程度，并进行肝纤维化Ishak评分；检测肝组织中核苷酸结合结构域富含亮氨酸重复序列和含热蛋白结构域受体3（NLRP3）、胱天蛋白酶1（caspase-1）、消皮素D（GSDMD）、白细胞介素18（IL-18）、IL-1β mRNA及蛋白的表达情况。

结果

与模型组比较，鳖龙软肝汤低、高剂量组大鼠一般状态（低剂量组除外）和肝脏质地、表面结节和肿瘤块、炎症细胞浸润及异形细胞数量均有所改善；肝指数（低剂量组除外），Ishak评分（低剂量组除外），血清中ALT、AST含量，以及肝组织中NLRP3、caspase-1、GSDMD、IL-18、IL-1β mRNA和蛋白的表达量均显著降低（

＜0.05），其中高剂量组上述部分指标显著低于低剂量组（

＜0.05）。

结论

鳖龙软肝汤可抑制大鼠肝癌进程，减轻肝损伤，其作用机制可能与抑制NLRP3/caspase-1/GSDMD信号通路、改善炎症反应有关。

Abstract

OBJECTIVE

To explore the effects and mechanism of Bielong ruangan decoction on liver cancer model rats.

METHODS

Thirty-two male SD rats were randomly divided into control group， model group， and Bielong ruangan decoction low-dose and high-dose groups [6.84， 27.36 g/（kg·d）， by raw material]， with 8 rats in each group. Except for the control group， other groups were intraperitoneally injected with diethylnitrosamine （DEN） 50 mg/kg （once a week， for 16 consecutive weeks） to induce liver cancer model. At the 8th week of DEN injection， Bielong ruangan decoction low-dose and high-dose groups were orally administered with the corresponding medication， twice a day， until the 16th week. The general condition of rats in each group was observed during the experimental period. After the final administration， the body weight and liver mass were weighed， and the liver indexes were calculated； serum contents of alanine transaminase （ALT） and aspartate transaminase （AST） were determined； the appearance， pathological morphology and degree of fibrosis of liver were observed； Ishak scoring for liver fibrosis was performed； the mRNA and protein expressions of nucleotide-binding domain leucine-rich repeat and pyrin domain-containing receptor 3 （NLRP3）， caspase-1， gasdermin D （GSDMD）， interleukin-18 （IL-18）， IL-1β in liver tissue were detected.

RESULTS

Compared with the model group， the general condition of rats （except for the low-dose group）， liver texture， surface nodules and tumors， inflammatory cell infiltration and abnormal cell amount were all improved in Bielong ruangan decoction low-dose and high-dose groups. Liver index （except for low-dose group）， Ishak score （except for low-dose group）， the serum contents of ALT and AST， as well as the mRNA and protein expressions of NLRP3， caspase-1， GSDMD， IL-18 and IL-1β in liver tissue were reduced significantly （

＜0.05）， with some of above indicators in high-dose group being significantly lower than those in low-dose group （

＜0.05）.

CONCLUSIONS

Bielong ruangan decoction can inhibit the progression of liver cancer in rats and reduce liver damage. Its mechanism of action may be related to the inhibition of the NLRP3/caspase-1/GSDMD signaling pathway and the improvement of inflammatory response.

关键词

鳖龙软肝汤肝癌NLRP3/caspase-1/GSDMD信号通路炎症反应

Keywords

liver cancerNLRP3/caspase-1/GSDMD signaling pathwayinflammatory response

references

SUNG H，FERLAY J，SIEGEL R L，et al. Global cancer statistics 2020：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin，2021，71（3）：209-249.

国家卫生健康委员会医政医管局. 原发性肝癌诊疗指南：2022年版[J]. 中华肝脏病杂志，2022，30（4）：367-388.

Bureau of Medical Administration，National Health Commission. Standardization for diagnosis and treatment of hepatocellular carcinoma：2022 edition[J]. Chin J Hepatol，2022，30（4）：367-388.

刘江荣，王霞，胡玫. 精准医学下肝癌研究热点的可视化分析[J/OL].肿瘤综合治疗电子杂志，2022，8（1）：99-106[2024-07-21]. http：//www.jmcm2018.com/CN/10.12151/JMCM.2022.01-15http://www.jmcm2018.com/CN/10.12151/JMCM.2022.01-15. DOI：10.12151/JMCM.2022.01-05http://dx.doi.org/10.12151/JMCM.2022.01-05.

LIU J R，WANG X，HU M. Analysis of research hotspots of liver cancer under precision medicine based on bibliometric[J/OL]. J Multidiscip Cancer Manag （Electronic Version），2022，8（1）：99-106[2024-07-21]. http：//www.jmcm2018.com/CN/10.12151/JMCM.2022.01-15http://www.jmcm2018.com/CN/10.12151/JMCM.2022.01-15. DOI：10.12151/JMCM.2022.01-05http://dx.doi.org/10.12151/JMCM.2022.01-05.

HSUEH K C，LEE T Y，KOR C T，et al. The role of liver transplantation or resection for patients with early hepatocellular carcinoma[J]. Tumor Biol，2016，37（3）：4193-4201.

雷久士，李观林，郭建生，等. 鳖龙软肝片对实验大鼠肝纤维化的病理研究[J]. 湖南中医学院学报，2000，20（1）：22-23.

LEI J S，LI G L，GUO J S，et al. Pathological study of Bielongruangan tablet on hepatic fibrosis in experimental rats[J]. J Hunan Coll Tradit Chin Med，2000，20（1）：22-23.

王雅，熊焰，张涛，等. 鳖龙软肝片抗肝纤维化临床观察[J]. 湖南中医药大学学报，2010，30（9）：181-183.

WANG Y，XIONG Y，ZHANG T，et al. Clinical study of Bielong ruangan capsule on liver fibrosis[J]. J Tradit Chin Med Univ Hunan，2010，30（9）：181-183.

石文静，彭杰，张涛，等. 鳖龙软肝片联合抗病毒药治疗乙型肝炎肝硬化的回顾性临床研究[J]. 湖南中医药大学学报，2024，44（3）：473-478.

SHI W J，PENG J，ZHANG T，et al. Retrospective clinical study on Bielong ruangan tablets combined with antiviral drugs in treating hepatitis B cirrhosis[J]. J Hunan Univ Chin Med，2024，44（3）：473-478.

黄鑫悦，晁旭，黄峰. 细胞焦亡在原发性肝癌进展中的作用研究进展[J]. 药物评价研究，2021，44（7）：1535-1540.

HUANG X Y，CHAO X，HUANG F. Research progress on role of pyroptosis in progress of primary liver cancer[J]. Drug Eval Res，2021，44（7）：1535-1540.

KELLEY N，JELTEMA D，DUAN Y H，et al. The NLRP3 inflammasome：an overview of mechanisms of activation and regulation[J]. Int J Mol Sci，2019，20（13）：3328.

TOLBA R，KRAUS T，LIEDTKE C，et al. Diethylnitrosamine（DEN）-induced carcinogenic liver injury in mice[J]. Lab Anim，2015，49（Suppl. 1）：59-69.

黄守坚. 新药临床前研究的剂量设计要点[C]//中国药学会. 第二届药品技术审评研讨会论文集.北京：中国药学会，2003：423-425.

HUANG S J. Key points of dose design in preclinical stu-dies of new drugs[C]//Chinese Pharmaceutical Association. Proceedings of the Second Drug Technical Review Seminar. Beijing：Chinese Pharmaceutical Association，2003：423-425.

徐叔云，卞如濂，陈修.药理实验方法学[M]. 3版. 北京：人民卫生出版社，2002：202-204.

XU S Y，BIAN R L.CHEN X. Pharmacological experimental methodology[M]. 3rd edition. Beijing：People’s Health Publishing House，2002：202-204.

GOODMAN Z D. Grading and staging systems for inflammation and fibrosis in chronic liver diseases[J]. J Hepatol，2007，47（4）：598-607.

蒋益兰，潘敏求，黄钢. 原发性肝癌中西医结合诊疗专家共识[J]. 中医药导报，2021，27（9）：101-107.

JIANG Y L，PAN M Q，HUANG G. Consensus on diagnosis and treatment of primary liver cancer with integrated traditional Chinese and western medicine[J]. Guid J Tradit Chin Med Pharm，2021，27（9）：101-107.

聂广，张赤志，唐智敏，等. 拓展王伯祥教授“肝络瘀阻” 学说构建中医肝病分期辨证体系[J]. 中西医结合肝病杂志，2022，32（9）：773-779，786.

NIE G，ZHANG C Z，TANG Z M，et al. Expanding Professor Wang Boxiang’s theory of “stasis of liver colla-teral” and constructing stage syndrome differentiation system of liver disease in traditional Chinese medicine[J]. Chin J Integr Tradit West Med Liver Dis，2022，32（9）：773-779，786.

顾姣，邵铭. 邵铭教授治疗肝硬化的活血化瘀法用药经验[J]. 中医临床研究，2019，11（5）：59-61.

GU J，SHAO M. Experience of Professor Shao Ming in treating cirrhosis with the Huoxue huayu therapy[J]. Clin J Chin Med，2019，11（5）：59-61.

王明亮，彭蕴茹. 二乙基亚硝胺诱导小鼠肝纤维化动态模型的建立及病理机制初探[J]. 实验动物科学，2021，38（3）：1-9.

WANG M L，PENG Y R. To establish a dynamic model of hepatic fibrosis induced by diethylnitrosamine and explore its pathological mechanism in mice[J]. Lab Anim Sci，2021，38（3）：1-9.

何欢欢，宋新强，王帅. 细胞焦亡在癌症发生发展及治疗中作用的研究进展[J]. 中国药理学与毒理学杂志，2022，36（7）：536-543.

HE H H，SONG X Q，WANG S. Roles of pyroptosis in occurrence，development and treatment of cancer：a review[J]. Chin J Pharmacol Toxicol，2022，36（7）：536-543.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Improvement effects and mechanism of sinomenine on non-alcoholic steatohepatitis in mice

Improvement effect and mechanism of triptolide on sciatica rats by regulating cGAS/STING signaling pathway

Improvement effects of poria acid on insulin resistance in rats with polycystic ovary syndrome and its mechanism

Inhibitory effects of formononetin on lipopolysaccharide-induced apoptosis and inflammatory response in alveolar epithelial cells

Effect and mechanism of PNU-282987 on cognitive function of temporal lobe epilepsy model rats

Related Author

WENG Liangkun

ZENG Cheng

JING Yanlin

ZHANG Huiyu

MENG Yan

LIN Shuxia

YAN Gaixia

JIANG Xiaomei

Related Institution

Key Specialty of Clinical Pharmacy， the First Affiliated Hospital of Guangdong Pharmaceutical University

Center for Drug Research and Development， Guangdong Pharmaceutical University

College of Traditional Chinese Medicine Health Service， Shanxi Datong University

Dept. of Gynecology， Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

Dept. of Obstetrics and Gynecology， the Seventh People’s Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

Address：8th Floor, Sihuan Building, No. 129 Daping Main Street, Yuzhong District, Chongqing, China Postal code：400042
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰